ZYME — Zymeworks Inc.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1937653 ·
Last close
$25.84
Market Cap
$1.78B
52W High
$31.97
52W Low
$21.52
ADV30
1,328,437
Next earnings
2026-11-09
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Sep 2026 | 256,460,000 | — | 177,634,000 | 173,700,000 | 1,176,413,000 | 100,464,000 | 918,160,000 |
| Jun 2026 | 4,590,000 | — | -42,145,000 | -45,019,000 | 396,964,000 | 179,413,000 | 316,595,000 |
| Mar 2026 | 2,408,000 | — | -47,149,000 | -44,162,000 | 478,215,000 | 244,282,000 | 314,626,000 |
| Dec 2025 | 2,515,000 | — | -44,120,000 | -41,209,000 | 346,527,000 | 41,157,000 | 78,026,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-111,964,000
Investing CF
$-297,370,000
Financing CF
$444,875,000
CapEx
$-1,419,000
Dividends Paid
—
Buybacks
$-165,571,000
EPS Diluted TTM
$0.52
As of
2026-11-15
Balance + Analyst (yfinance extras)
Retained Earnings
$-1,009,530,000
Inventory
—
Receivables
$413,861,000
ST Investments
$0
EBIT TTM
$52,829,000
Pretax Income TTM
$40,124,000
Interest Exp TTM
$15,346,000
Analysts
14
Yahoo Snapshot (yfinance, live)
Total Revenue
$265,972,992
EBITDA
$65,140,000
Free Cash Flow
$-195,686,752
Enterprise Value
$1,764,029,312
Total Cash
$100,464,000
Total Debt
$53,128,000
Shares Out
69,030,691
Trailing EPS
$0.53
Book Value
$3.63
ROE
15.0%
ROA
4.8%
Div Yield
0.00%
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 105,965,000 | -92,535,000 | -81,130,000 | 346,527,000 | 78,026,000 | 268,501,000 | -33,005,000 |
| Dec 2024 | 76,304,000 | -119,817,000 | -122,695,000 | 463,091,000 | 124,323,000 | 338,768,000 | -110,058,000 |
| Dec 2023 | 76,012,000 | -138,007,000 | -118,674,000 | 580,880,000 | 116,074,000 | 464,806,000 | -118,324,000 |
| Dec 2022 | 412,482,000 | 130,486,000 | 124,341,000 | 648,725,000 | 155,769,000 | 492,956,000 | 144,109,000 |
TTM Snapshot
Revenues TTM
$37,127,000
NetIncome TTM
$-149,992,000
OpCashFlow TTM
—
Assets (Latest)
$396,964,000
Forward EPS
$0.52
Max Pain — expiry 2027-12-17
max pain strike: $30.00 · spot: $26.04 · call oi: 1,615 · put oi: 3,247
Expected Move to 2027-12-17:
±$11.50
(44.16%) —
implied range
$14.54 –
$37.54
· ATM straddle on $25.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| AGIO | AGIOS PHARMACEUTICALS, INC. | $1.79B | $29.89 | — |
| TRAX | First Tracks Biotherapeutics, Inc. | $1.83B | $43.57 | — |
| ETON | Eton Pharmaceuticals, Inc. | $1.84B | $63.65 | — |
| STOK | Stoke Therapeutics, Inc. | $1.73B | $26.41 | — |
| RARE | Ultragenyx Pharmaceutical Inc. | $1.70B | $16.70 | — |
News headlines (Yahoo Finance, 1h cache)
Zymeworks Announces $200 Million Share Repurchase Authorization
2026-11-16 11:00 · Yahoo
Milestone Payment Lifts Zymeworks Stock Outlook After Profitable Quarter
2026-11-12 23:23 · Yahoo
Zymeworks Inc. (ZYME) Misses Q3 Earnings Estimates
2026-11-09 22:35 · Yahoo
Zymeworks Provides Corporate Update and Reports Third Quarter 2026 Financial Results
2026-11-09 21:05 · Yahoo
Zymeworks (ZYME) Gains Fresh Backing On Trial Data And Roche Deal
2026-11-04 04:33 · Yahoo
Zymeworks Inc. (ZYME) to Report Q3 Results: Wall Street Expects Earnings Growth
2026-10-29 13:00 · Yahoo
Zymeworks Highlights ZW191 Ovarian Cancer Responses, Roche Deal Upside
2026-10-27 23:04 · Yahoo
Faeth Appoints Adam Schayowitz, Ph.D., MBA, Head of Research and Development at Zymeworks, to Board of Directors
2026-10-27 11:00 · Yahoo
Zymeworks Presents New Phase 1 Data for Folate Receptor Alpha-Targeting Antibody-Drug Conjugate ZW191 at ESMO Congress 2026
2026-10-24 06:30 · Yahoo
Zymeworks stock surges on $813M Roche licensing deal
2026-10-23 13:25 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.